Vor Biopharma Q2 Adj. EPS Misses Estimate
Vor Biopharma reports Q2 adjusted EPS of $(0.80), missing the $(0.70) estimate
Vor Biopharma (NASDAQ: VOR ) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent.
This is a 98.17 percent increase over losses of $(43.80) per share from the same period last year.